Update on the use of collagen/glycosaminoglycate skin substitute-six years of experiences with artificial skin in 15 German burn centers.
The clinical use of an artificial skin substitute (Integra) has been celebrated enthusiastically as an improvement in burn therapy over a period of more than 10 years. Many case-reports have shown the positive effects of the treatment with Integra as a skin substitute. In this study we examine the alterations of Integra-usage in Germany. Fifteen German burn centres have been interviewed respectively over a time period of 6 years with interviews in the years 1999, 2001, and 2003. The goal of this study is to focus on the problems associated with the use of artificial skin and to create a manual for Integra-therapy including indication, pre-, intra-, and postoperative treatment. Since the first Integra Users seminar in Germany in 1999 repeated interviews have been conducted with fifteen German burn centres. The collected results of the last 6 years were evaluated. These results show a change in the indication for the therapy with artificial skin towards extensive full thickness burned patients and as extended indication especially for posttraumatic reconstruction. This article gives our guidelines for the usage and handling of Integra and shows that Integra is an important reconstructive dermal substitute for the severely burned or posttraumatic patient if handled by a skilled surgeon in a correct way.
Heitland
A
A
Department of Plastic and Reconstructive Surgery, Burns Unit, RWTH, University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.
Piatkowski
A
A
Noah
E M
EM
Pallua
N
N
D000891:Anti-Infective Agents, Local / Q000008:administration & dosage; D001672:Biocompatible Materials / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002053:Burn Units / Q000706:statistics & numerical data*; D002056:Burns / Q000473:pathology / Q000601:surgery*; D002809:Chondroitin Sulfates; D003094:Collagen; D003362:Cost-Benefit Analysis; D005858:Germany; D006025:Glycosaminoglycans; D006801:Humans; D018579:Patient Selection; D019990:Perioperative Care / Q000379:methods; D012189:Retrospective Studies; D017768:Skin, Artificial / Q000009:adverse effects / Q000191:economics / Q000706:statistics & numerical data*
D000891:Anti-Infective Agents, Local; D001672:Biocompatible Materials; D006025:Glycosaminoglycans; C018303:glycosaminoglucuronates; C114835:integra artificial skin; D002809:Chondroitin Sulfates; D003094:Collagen